FDA Oks Provention Bio's Tzield To Delay Onset Of Type 1 Diabetes

The U.S. Food and Drug Administration said it has approved Provention Bio Inc.'s Tzield (teplizumab-mzwv) injection to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes. In pre-market activity on Nasdaq, Provention Bio shares were gaining around 9.7 percent to trade at $9.04.

from RTT - Top Story https://ift.tt/UgASQnp
via IFTTT